Liepa, Skopina/ BORENIUS advised Abbott in this global transaction regarding Latvian law matters, including M&A, employment, data protection and pharmacy.

Abbott has completed its EUR 4.5 billion ($6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets.

Abbott has a strong portfolio of specialty pharmaceuticals and Solvay brings successful, consistently performing products – including branded generics – that will further diversify Abbott's pharmaceutical business and provide significant growth opportunities.

Solvay Pharmaceuticals is now part of Abbott's global Pharmaceutical Products Group.